TY - JOUR
T1 - Childhood-onset Takayasu arteritis
AU - Millan, Pamela
AU - Gavcovich, Tara B.
AU - Abitbol, Carolyn
N1 - Funding Information:
This work was supported in part by the Liliane Barbarosh Pediatric Renal Research and Educational Fund at the University of Miami.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Purpose of reviewTakayasu arteritis is a rare chronic granulomatous large vessel vasculitis that predominantly affects the aorta and its branches. The purpose of this review is to unite the current knowledge regarding the pathophysiology, cause, and epidemiology as well as diagnosis, prognosis, and treatment of this condition in children.Recent findingsAlthough the etiopathogenesis is not fully understood, studies suggest an autoimmune basis for the disease as well as a genetic predisposition. It is a disease primarily affecting young women with up to a third of cases with onset in childhood. There are distinct features of childhood-onset Takayasu arteritis (cTA) that merit this separate review. Diagnostic criteria and clinical manifestations are unique in pediatric patients with renovascular hypertension being the most prevalent presentation. Traditional treatments involving high-dose corticosteroids and cytotoxic agents are being reconsidered for less toxic contemporary biologic agents. Current algorithms for treatment include early introduction of corticosteroid-sparing agents, such as methotrexate or mycophenolate as well as tumor necrosis factor-alpha (TNF-α ) inhibitor (infliximab, adalimumab) and/or interleukin-6 (IL-6) receptor inhibitor (tocilizumab).SummaryEarly diagnosis of cTA with goals to develop effective and well tolerated treatment paradigms are essential to improve the long-term prognosis of this rare and devastating disease.
AB - Purpose of reviewTakayasu arteritis is a rare chronic granulomatous large vessel vasculitis that predominantly affects the aorta and its branches. The purpose of this review is to unite the current knowledge regarding the pathophysiology, cause, and epidemiology as well as diagnosis, prognosis, and treatment of this condition in children.Recent findingsAlthough the etiopathogenesis is not fully understood, studies suggest an autoimmune basis for the disease as well as a genetic predisposition. It is a disease primarily affecting young women with up to a third of cases with onset in childhood. There are distinct features of childhood-onset Takayasu arteritis (cTA) that merit this separate review. Diagnostic criteria and clinical manifestations are unique in pediatric patients with renovascular hypertension being the most prevalent presentation. Traditional treatments involving high-dose corticosteroids and cytotoxic agents are being reconsidered for less toxic contemporary biologic agents. Current algorithms for treatment include early introduction of corticosteroid-sparing agents, such as methotrexate or mycophenolate as well as tumor necrosis factor-alpha (TNF-α ) inhibitor (infliximab, adalimumab) and/or interleukin-6 (IL-6) receptor inhibitor (tocilizumab).SummaryEarly diagnosis of cTA with goals to develop effective and well tolerated treatment paradigms are essential to improve the long-term prognosis of this rare and devastating disease.
KW - childhood renovascular hypertension
KW - granulomatous vasculitis
KW - Takayasu arteritis
UR - http://www.scopus.com/inward/record.url?scp=85125554422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125554422&partnerID=8YFLogxK
U2 - 10.1097/MOP.0000000000001113
DO - 10.1097/MOP.0000000000001113
M3 - Review article
C2 - 35142753
AN - SCOPUS:85125554422
VL - 34
SP - 223
EP - 228
JO - Current Opinion in Pediatrics
JF - Current Opinion in Pediatrics
SN - 1040-8703
IS - 2
ER -